Research view
Switch to patient viewAcute myeloid leukaemia: trials that stopped early
Trials on Acute myeloid leukaemia that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
167 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.
Terminated
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Reason given in the registry “Sponsor Decision - Pipeline Reprioritization”
Quoted unchanged from ClinicalTrials.gov; record updated 11 Jun 2025.
- Ended
- May 2025
- Phase
- Phase 1
- Run by
- Caribou Biosciences, Inc.
- Registry record
- NCT06128044
Withdrawn
Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy
Reason given in the registry “The project was terminated as the genetic office did not approve it.”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Jun 2025.
- Phase
- Phase 2
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
- Registry record
- NCT06770257
Terminated
Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy
Reason given in the registry “The number of participants in the study did not meet expectations”
Quoted unchanged from ClinicalTrials.gov; record updated 30 May 2025.
- Ended
- Mar 2025
- Phase
- Phase 1/2
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
- Registry record
- NCT06449482
Withdrawn
Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor
Reason given in the registry “cprmc withdrawn”
Quoted unchanged from ClinicalTrials.gov; record updated 25 May 2025.
- Phase
- Phase 1
- Run by
- City of Hope Medical Center
- Registry record
- NCT06572631
Terminated
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Reason given in the registry “supporting/funding source decided to de-prioritize and stop development of DS-1594”
Quoted unchanged from ClinicalTrials.gov; record updated 23 May 2025.
- Ended
- Nov 2023
- Phase
- Phase 1/2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT04752163
Terminated
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)
Reason given in the registry “Business Reasons”
Quoted unchanged from ClinicalTrials.gov; record updated 21 May 2025.
- Ended
- Dec 2023
- Phase
- Phase 1
- Run by
- Merck Sharp & Dohme LLC
- Registry record
- NCT05038800
Terminated
XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia
Reason given in the registry “Drug expired May 31, 2024.”
Quoted unchanged from ClinicalTrials.gov; record updated 8 May 2025.
- Ended
- Nov 2024
- Phase
- Phase 1
- Run by
- Ehab L Atallah
- Registry record
- NCT05038644
Terminated
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
Reason given in the registry “The study was terminated early due to slow accrual and low level of interest both by the sponsor and by the department”
Quoted unchanged from ClinicalTrials.gov; record updated 8 May 2025.
- Ended
- Jun 2024
- Phase
- Phase 1/2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT03576547
Withdrawn
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
Reason given in the registry “Study disapproved by internal scientific review committee on re-review; study will no longer move forward”
Quoted unchanged from ClinicalTrials.gov; record updated 22 Apr 2025.
- Phase
- Phase 2
- Run by
- University of Florida
- Registry record
- NCT05766514
Terminated
Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia
Reason given in the registry “Despite a recruitment target that was not met, we managed to achieve more than 50% of inclusions and 33% of deaths, enabling us to carry out an initial analysis of the primary endpoint”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Apr 2025.
- Ended
- May 2024
- Phase
- Phase 3
- Run by
- University Hospital, Toulouse
- Registry record
- NCT03765541
Terminated
Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies
Reason given in the registry “Terminated - alignment of strategic priorities”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Apr 2025.
- Ended
- Mar 2025
- Phase
- Phase 1
- Run by
- Blueprint Medicines Corporation
- Registry record
- NCT05609942
Terminated
Investigating Integrative Therapies for Symptom Management in Adults With Acute Leukemia
Reason given in the registry “The PIs left the institution.”
Quoted unchanged from ClinicalTrials.gov; record updated 7 Apr 2025.
- Ended
- Mar 2025
- Run by
- University of Florida
- Registry record
- NCT04185428
Terminated
Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)
Reason given in the registry “Interim analysis determined that study reached a safety stopping rule”
Quoted unchanged from ClinicalTrials.gov; record updated 7 Apr 2025.
- Ended
- May 2024
- Phase
- Phase 3
- Run by
- University of Florida
- Registry record
- NCT03016130
Terminated
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Reason given in the registry “Low accrual”
Quoted unchanged from ClinicalTrials.gov; record updated 6 Apr 2025.
- Ended
- Mar 2024
- Phase
- Phase 2
- Run by
- Memorial Sloan Kettering Cancer Center
- Registry record
- NCT03615105
Terminated
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
Reason given in the registry “Study was terminated due to futility”
Quoted unchanged from ClinicalTrials.gov; record updated 4 Apr 2025.
- Ended
- Apr 2024
- Phase
- Phase 3
- Run by
- Gilead Sciences
- Registry record
- NCT05079230
Terminated
A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS
Reason given in the registry “The protocol was terminated on the basis of a reprioritization of organizational allocation of resources for clinical research programs.”
Quoted unchanged from ClinicalTrials.gov; record updated 25 Mar 2025.
- Ended
- Mar 2024
- Phase
- Phase 1
- Run by
- GlaxoSmithKline
- Registry record
- NCT05424380
Withdrawn
DEC-C and Thioguanine for R/R AML
Reason given in the registry “Difficultly enrolling”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Mar 2025.
- Ended
- Apr 2024
- Phase
- Phase 2
- Run by
- Columbia University
- Registry record
- NCT06351306
Withdrawn
A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia
Reason given in the registry “PI Request”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Mar 2025.
- Ended
- Mar 2025
- Phase
- Phase 1/2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT06113289
Terminated
A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS
Reason given in the registry “Change in corporate strategy”
Quoted unchanged from ClinicalTrials.gov; record updated 7 Mar 2025.
- Ended
- Apr 2024
- Phase
- Phase 1
- Run by
- Aptose Biosciences Inc.
- Registry record
- NCT04477291
Terminated
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Reason given in the registry “Strategic considerations”
Quoted unchanged from ClinicalTrials.gov; record updated 6 Mar 2025.
- Ended
- Feb 2025
- Phase
- Phase 1
- Run by
- AbbVie
- Registry record
- NCT06068868
Terminated
Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML
Reason given in the registry “Collaborator's decision”
Quoted unchanged from ClinicalTrials.gov; record updated 26 Feb 2025.
- Ended
- Jul 2024
- Phase
- Early phase 1
- Run by
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
- Registry record
- NCT06110208
Terminated
Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia
Reason given in the registry “didn't reach the primary endpoint”
Quoted unchanged from ClinicalTrials.gov; record updated 25 Feb 2025.
- Ended
- Dec 2024
- Phase
- Phase 2
- Run by
- Niguarda Hospital
- Registry record
- NCT03686345
Terminated
Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]
Reason given in the registry “low recruitment rate”
Quoted unchanged from ClinicalTrials.gov; record updated 20 Feb 2025.
- Ended
- Feb 2025
- Phase
- Phase 1/2
- Run by
- Centre Leon Berard
- Registry record
- NCT06150040
Terminated
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
Reason given in the registry “Study discontinued due to futility.”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Feb 2025.
- Ended
- Mar 2024
- Phase
- Phase 3
- Run by
- Gilead Sciences
- Registry record
- NCT04778397
Terminated
Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia
Reason given in the registry “poor enrollment”
Quoted unchanged from ClinicalTrials.gov; record updated 30 Jan 2025.
- Ended
- Jan 2024
- Phase
- Phase 2
- Run by
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Registry record
- NCT04342962
Withdrawn
Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease
Reason given in the registry “Kits were not available due to lack of sponsorship”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Jan 2025.
- Ended
- Nov 2024
- Run by
- Ugur Arzu Kulu
- Registry record
- NCT06200441
Terminated
Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission
Reason given in the registry “PI decision to close study early due to limited data due to accrual goal not being met”
Quoted unchanged from ClinicalTrials.gov; record updated 16 Jan 2025.
- Ended
- Aug 2024
- Phase
- Phase 2
- Run by
- University of Florida
- Registry record
- NCT04914676
Terminated
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Reason given in the registry “Study was terminated by the sponsor based on insufficient tolerability and efficacy to proceed beyond Part 1b.”
Quoted unchanged from ClinicalTrials.gov; record updated 20 Dec 2024.
- Ended
- May 2024
- Phase
- Phase 1/2
- Run by
- Hoffmann-La Roche
- Registry record
- NCT04029688
Terminated
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia
Reason given in the registry “Administratively Complete”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Dec 2024.
- Ended
- Nov 2024
- Phase
- Phase 1
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT04526795
Terminated
A Study of TAS1440 With ATRA in Subjects With r/r AML
Reason given in the registry “The study was terminated due to the changing treatment landscape, difficulty in enrolling eligible participants, and little likelihood of providing meaningful clinical benefit for the participants.”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Dec 2024.
- Ended
- Feb 2024
- Phase
- Phase 1
- Run by
- Taiho Oncology, Inc.
- Registry record
- NCT04282668
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.